HeartBeam (NASDAQ: BEAT) has announced a strategic reorganization designed to accelerate execution, expand global market reach, and improve capital efficiency as it advances the commercialization of its cardiac monitoring technology. The company aims to leverage its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection.
Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams intended to streamline decision-making, improve accountability, and reduce costs. Former CEO Robert Eno will transition into a consulting role. The reorganization reflects HeartBeam's commitment to achieving its commercialization goals more efficiently.
HeartBeam plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. The company's platform technology is designed for portable, cable-free devices that collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities.
This strategic shift comes as HeartBeam holds over 20 issued patents related to its technology enablement and aims to redefine cardiac health management through actionable heart intelligence. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, followed by clearance for the 12-lead ECG synthesis software in December 2025.
For more details, the full press release is available at https://ibn.fm/CTxXi. The latest news and updates relating to BEAT can be found in the company's newsroom at https://ibn.fm/BEAT.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. Undue reliance should not be placed on these forward-looking statements, which are based on information available as of the date hereof.
